Want to see NNVC full AI Analyst Report?
Top Page
NanoViricides
(NYSE MKT:NNVC)
Select Model
Select Model
Rating:51Neutral
Price Target:
$1.50
▲(32.74% Upside)
Action:Reiterated
Date:07/14/26
The score is held down mainly by weak fundamentals: no revenue, recurring losses, ongoing cash burn, and heightened uncertainty from unusually extreme TTM loss/cash outflow figures. Partially offsetting this are low balance-sheet leverage, a moderately positive technical setup with price above major moving averages, and a modestly supportive recent product/strategy update.
Positive Factors
Proprietary platform & focused antiviral R&D
NanoViricides’ proprietary nanoviricide platform is a durable competitive asset in antiviral drug development. A platform-centric model supports multiple programs and indications, enabling reuse of core chemistry and know-how across candidates, improving long-term pipeline optionality and R&D efficiency.
Negative Factors
No revenue; persistent net losses
The company remains pre-revenue with recurring annual net losses, a structural limitation for near-term self-sustainability. Continued operating losses erode equity and force reliance on external financing, which can dilute shareholders and divert management time to capital raises rather than purely scientific execution.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary platform & focused antiviral R&D
NanoViricides’ proprietary nanoviricide platform is a durable competitive asset in antiviral drug development. A platform-centric model supports multiple programs and indications, enabling reuse of core chemistry and know-how across candidates, improving long-term pipeline optionality and R&D efficiency.
Read all positive factors
NanoViricides (NNVC) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$34.70M
Dividend YieldN/A
Average Volume (3M)143.34K
Price to Earnings (P/E)―
Beta (1Y)1.05
Revenue GrowthN/A
EPS Growth37.68%
CountryUS
Employees7
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.43
Shares Outstanding22,982,817
10 Day Avg. Volume199,739
30 Day Avg. Volume143,335
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)2.82
Price to Sales (P/S)0.00
P/FCF Ratio-2.48
Enterprise Value/Market Cap0.60
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-159.92
Enterprise Value/Ebitda-2.75
Forecast
1Y Price Target
$6.00Price Target Upside430.97% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.35
Revenue Forecast (FY)$7.00M
NanoViricides Business Overview & Revenue Model
Company Description
NanoViricides, Inc. operates as a nano-biopharmaceutical entity, specializing in the research, development, and market introduction of pharmaceutical solutions to combat viral infections. The company's robust product pipeline includes a Human Coro...
How the Company Makes Money
null...
NanoViricides Financial Statement Overview
Summary
Income Statement
7
Very Negative
Balance Sheet
62
Positive
Cash Flow
18
Very Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -129.63K | 0.00 | 0.00 | -747.53K | 0.00 | 0.00 |
| EBITDA | -7.53M | -8.72M | -7.49M | -7.84M | -7.38M | -8.03M |
| Net Income | -8.09M | -9.47M | -8.29M | -8.59M | -8.11M | -8.82M |
Balance Sheet | ||||||
| Total Assets | 10.22M | 8.82M | 12.82M | 16.90M | 23.49M | 30.26M |
| Cash, Cash Equivalents and Short-Term Investments | 3.21M | 1.56M | 4.80M | 8.15M | 14.07M | 20.52M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 94.79K | 95.31K |
| Total Liabilities | 1.07M | 1.31M | 1.36M | 2.03M | 412.84K | 351.15K |
| Stockholders Equity | 9.15M | 7.52M | 11.46M | 14.87M | 23.08M | 29.91M |
Cash Flow | ||||||
| Free Cash Flow | -7.37M | -8.54M | -6.47M | -5.82M | -6.22M | -8.45M |
| Operating Cash Flow | -7.28M | -8.48M | -6.32M | -5.67M | -5.89M | -8.21M |
| Investing Cash Flow | -94.52K | -56.96K | -156.56K | -151.71K | -324.35K | -238.76K |
| Financing Cash Flow | 8.04M | 5.30M | 3.12M | -94.79K | -234.72K | 15.26M |
NanoViricides Technical Analysis
Positive
1.13
Price Trends
1.48
Positive
1.27
Positive
1.29
Positive
Market Momentum
0.04
Negative
60.73
Neutral
77.16
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NNVC, the sentiment is Positive. The current price of 1.13 is below the 20-day moving average (MA) of 1.40, below the 50-day MA of 1.48, and below the 200-day MA of 1.29, indicating a bullish trend. The MACD of 0.04 indicates Negative momentum. The RSI at 60.73 is Neutral, neither overbought nor oversold. The STOCH value of 77.16 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NNVC.
NanoViricides Risk Analysis
NanoViricides disclosed 51 risk factors in its most recent earnings report. NanoViricides reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
NanoViricides Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | $292.09M | 8.67 | -0.29% | ― | -100.00% | 72.96% | |
52 Neutral | $15.89M | >-0.01 | -68.21% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $34.70M | -3.82 | -92.69% | ― | ― | 37.68% | |
51 Neutral | $12.17M | -0.08 | ― | ― | ― | 80.65% | |
43 Neutral | $115.47M | 0.02 | 248.08% | ― | ― | ― |
* Healthcare Sector Average
NNVC
NanoViricides
1.65
0.05
3.12%
ENLV
Enlivex
6.67
-12.53
-65.26%
AKTX
Akari Therapeutics
13.40
-30.60
-69.55%
MBRX
Moleculin Biotech
2.21
-13.54
-85.97%
SABS
SAB Biotherapeutics
3.73
1.04
38.66%
NanoViricides Corporate Events
Business Operations and StrategyProduct-Related Announcements
NanoViricides Highlights NV-387 Strategy for Ebola Outbreak
Positive
May 21, 2026
NanoViricides disclosed that at the Alliance Global Partners Healthcare Companies Showcase on May 20, 2026, President and Executive Chairman Dr. Anil R. Diwan outlined how its lead candidate NV-387, along with a remdesivir-encapsulated version, ma...
Business Operations and StrategyPrivate Placements and Financing
NanoViricides Completes $2 Million Registered Direct Offering
Neutral
May 20, 2026
NanoViricides, Inc., a clinical-stage antiviral specialist, entered a securities purchase agreement on May 15, 2026, with a single institutional investor for a registered direct offering of common stock, pre-funded warrants, and common warrants. T...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.